Search

Begin New Search Topic Vaccine Political Geography Global Focus

21. The Gavi Mid-Term Review: Progress to Date and Prospects for 2021 and Beyond

Author:
Katherine E. Bliss
Publication Date:
01-2019
Content Type:
Working Paper
Institution:
Center for Strategic and International Studies (CSIS)
Abstract:
Gavi, The Vaccine Alliance, is making good progress toward meeting its current targets and is adapting its programs to continue delivering lifesaving products to the world’s poorest populations in the face of significant external pressures and challenges. However, as Gavi looks ahead to its next strategic phase and considers how conflicts and humanitarian crises, climate change, urbanization, and population growth will affect its work, it will need to evolve its partnership model and market-shaping approaches to ensure that the large numbers of poor children, including, potentially, many who live in non-eligible countries, are fully immunized. The Alliance highlighted its accomplishments and challenges faced thus far during the 2016-2020 work phase at a mid-term review held December 2018 in Abu Dhabi. The more than 300 participants included heads of state and ministers of health, as well as representatives of vaccine manufacturers, private sector organizations, donor governments, and implementing agencies. Over plenaries, panels, and breakaway sessions the diverse mix of Gavi partners considered ways to make the Alliance more effective in a changing geopolitical environment as it gears up for its next replenishment, to be held in 2020.
Topic:
Public Health, Vaccine, Medicine, and Immunization
Political Geography:
Global Focus

22. Why is There No AIDS Vaccine?

Author:
Michael Kremer and Christopher M. Snyder
Publication Date:
10-2004
Content Type:
Working Paper
Institution:
The John F. Kennedy School of Government at Harvard University
Abstract:
We argue that differences in timing of drug and vaccine consumption will lead firms to be biased against developing vaccines. Vaccines are sold before consumers are infected, when they still have private information regarding their infection risk, whereas drugs are sold after consumers are infected, when those with positive valuation have no private information on infection risk. Calibrations suggest that, for sexually transmitted diseases, for which infection risk is highly heterogeneous across consumers, producer surplus from drugs may exceed that from vaccines by a factor of four. Consistent with the model, empirical tests suggest vaccines are particularly unlikely to be developed for sexually transmitted diseases. Biases against vaccines are exacerbated by the durability of vaccines and by the interaction between the timing of vaccine and drug consumption and the temporary protection of intellectual property rights. We extend the analysis to allow for government procurement and for income heterogeneity among consumers. Given that antiretroviral drugs are difficult to deliver in the poor countries where most people infected with HIV/AIDS live, biases against developing a vaccine raise enormous public health concerns.
Topic:
HIV/AIDS, Health, Public Health, and Vaccine
Political Geography:
Global Focus